Drug Type Small molecule drug |
Synonyms Bleximenib, JNJ-75276617, JNJ 6617 + [4] |
Target |
Mechanism MLL1 inhibitors(lysine methyltransferase 2A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H50FN7O3 |
InChIKeyPDUGAXSIWNMIBQ-HHHXNRCGSA-N |
CAS Registry2654081-35-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
acute leukemia | Phase 2 | US | 19 May 2021 | |
acute leukemia | Phase 2 | JP | 19 May 2021 | |
acute leukemia | Phase 2 | AU | 19 May 2021 | |
acute leukemia | Phase 2 | FR | 19 May 2021 | |
acute leukemia | Phase 2 | ES | 19 May 2021 | |
acute leukemia | Phase 2 | GB | 19 May 2021 | |
Acute Lymphoblastic Leukemia | Phase 2 | US | 19 May 2021 | |
Acute Lymphoblastic Leukemia | Phase 2 | JP | 19 May 2021 | |
Acute Lymphoblastic Leukemia | Phase 2 | AU | 19 May 2021 | |
Acute Lymphoblastic Leukemia | Phase 2 | FR | 19 May 2021 |
NCT05453903 (EHA2024) Manual | Phase 1 | Acute Myeloid Leukemia KMT2A Mutation | NPM1 Mutation | 45 | ryxlpriqjf(acyeqpjmec) = 87% (39/45) of pts experienced ≥1 treatment-related AE (TRAE) attributed to any study treatment (allgrades); nausea (38%), vomiting (31%), and thrombocytopenia (31%) were the most common. fttdcaxhts (yzuapodjts ) View more | Positive | 14 May 2024 |